Last reviewed · How we verify
Fecal Microbiota Transplant
At a glance
| Generic name | Fecal Microbiota Transplant |
|---|---|
| Also known as | FMT, Fecal transplant, stool transplant, FMT Microbiota Preparation, FEDEX |
| Sponsor | Massachusetts General Hospital |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (PHASE2)
- Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis (PHASE3)
- Effect of Oral Microbiota on MDRO Decolonization (PHASE1, PHASE2)
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Nationality in the Treatment of IBD (NA)
- Fecal Microbiota Transplant (PHASE4)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC (PHASE2)
- Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fecal Microbiota Transplant CI brief — competitive landscape report
- Fecal Microbiota Transplant updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI